RxDoctor Payments Data

Diana Dillman, DO

Family Medicine · Jenison, MINPI 1235192188

Payments from drug & device makers

$7,142in general payments, 2019–2025

Across 72 payments — averaging $99.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • AstraZeneca$1K
  • Novo Nordisk$862
  • Gilead$513
  • Boehringer Ingelheim$494
  • Sanofi-aventis U.S. LLC$359
  • plus $1K from 7 others

What the payments were for

  • Food & beverage$7,125100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,142 in reported general payments places this provider in the 90th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$14,783
Medicare patients
100
Services billed
254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide74$96,382
TrulicityDulaglutide70$73,309
EliquisApixaban56$70,006
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$35,084
FarxigaDapagliflozin Propanediol28$32,778
OzempicSemaglutide23$28,416
JanuviaSitagliptin Phosphate24$26,552
XareltoRivaroxaban20$26,451
Repatha SureclickEvolocumab28$23,001
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$19,609
TradjentaLinagliptin20$18,491
JardianceEmpagliflozin11$18,240
Atorvastatin Calcium532$8,787
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$8,708
DuleraMometasone/Formoterol25$7,718

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$319$169,691144 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,384$41,48642 claims
Boehringer IngelheimTradjenta, Jardiance$494$36,73131 claims
Novo NordiskOzempic$862$28,41623 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$231$4,53611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Jenison

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →